Press Releases
Cytheris and CITN announce selection of recombinant interleukin-7 (CYT107) for initial studies at member institutions
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, and the Cancer Immunotherapy Trials Network (CITN),...
Press Releases
Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C
Roche announced that it has entered into agreements with Merck, known as MSD outside the United States, through their respective subsidiaries, to improve the treatment,...
Press Releases
FDA approves linagliptin tablets for the treatment of type 2 diabetes
Boehringer Ingelheim and Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along...
Press Releases
The American Society of Clinical Oncology and CollabRx Partner to Develop Online Apps for Planning Cancer Treatment
The American Society of Clinical Oncology (ASCO), the world's leading professional organization representing physicians who care for people with cancer, and CollabRx, an organization that...
Press Releases
The European Commission Approves Pfizer’s Revatio for the Treatment of Pulmonary Arterial Hypertension in Children
Pfizer Inc. announced that Revatio® (sildenafil citrate) has been approved by the European Commission for the treatment of pediatric patients aged 1 to 17 years...
Press Releases
Almac Introduces selectAZyme
Almac’s biocatalysis business has expanded from its 2009 launch with the sale of six enzyme screening kits, to the current supply of 100s of kgs...
Press Releases
ISTA Pharmaceuticals Reports Positive, Topline Results From Its Phase 2 Clinical Trial of Bepotastine Besilate Nasal Spray
ISTA Pharmaceuticals, Inc. announced positive, topline results from its Phase 2 dose-ranging, environmental clinical trial of bepotastine besilate nasal spray for the treatment of symptoms...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.